哮喘与COVID-19风险:系统综述与Meta分析
该系统综述与Meta分析纳入51项设有非哮喘对照组的观察性研究,评估哮喘患者感染SARS-CoV-2及COVID-19不良结局的风险。合并结果显示哮喘患者感染COVID-19的风险比非哮喘组降低(RR 0.83,95%CI 0.73-0.95,p=0.01),住院、ICU入住、呼吸机使用及死亡风险组间无统计学显著差异。按洲亚组分析显示美洲、欧洲和亚洲之间在感染、ICU入住、呼吸机使用和死亡风险上存在显著差异。
要点
- 哮喘患者感染COVID-19的风险较非哮喘组降低(RR 0.83,95%CI 0.73-0.95,p=0.01)。
- 哮喘与COVID-19住院、ICU入住、呼吸机使用及死亡风险无统计学显著关联。
- 不同洲之间COVID-19结局存在显著差异,非洲和南美洲研究较少需进一步验证。
核心结论
- 哮喘患者感染SARS-CoV-2的风险较非哮喘组降低,住院、ICU入住、呼吸机使用及死亡风险无统计学显著差异。
- 按洲亚组分析显示美洲、欧洲和亚洲之间在感染、ICU入住、呼吸机使用和死亡风险上存在显著差异。
研究设计与样本
- 纳入设有非哮喘对照组的51项研究,采用Sidik-Jonkman随机效应模型合并患病率和风险比。
主要发现
- COVID-19阳性病例中哮喘的合并患病率为8.08%(95%CI 6.87-9.30%)。
- 感染COVID-19的风险比RR为0.83(95%CI 0.73-0.95,p=0.01)。
- 住院风险比RR为1.18(95%CI 0.98-1.42,p=0.08)。
- ICU入住风险比RR为1.21(95%CI 0.97-1.51,p=0.09)。
- 呼吸机使用风险比RR为1.06(95%CI 0.82-1.36,p=0.65);死亡风险比RR为0.94(95%CI 0.76-1.17,p=0.58)。
临床怎么用
- 哮喘患者感染COVID-19的风险较非哮喘人群降低,临床不应默认哮喘为感染高危因素。
- 哮喘患者感染后住院、ICU入住、呼吸机使用及死亡风险与非哮喘组无显著差异,但需结合洲际差异个体化评估。
局限性
- 非洲和南美洲来源研究较少,需更多研究确认风险特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individual case series and cohort studies have reported conflicting results in people with asthma on the vulnerability to and risk of mortality from coronavirus disease 2019 (COVID-19). RESEARCH QUESTION: Are people with asthma at a higher risk of being infected or hospitalised or poorer clinical outcomes from COVID-19? METHODS: A systematic review and meta-analysis based on five main databases including the World Health Organization COVID-19 database between 1 December 2019 and 11 July 2021 on studies with a control (non-asthma) group was conducted. Prevalence and risk ratios were pooled using Sidik-Jonkman random-effects meta-analyses. FINDINGS: 51 studies with an 8.08% (95% CI 6.87-9.30%) pooled prevalence of people with asthma among COVID-19 positive cases. The risk ratios were 0.83 (95% CI 0.73-0.95, p=0.01) for acquiring COVID-19; 1.18 (95% CI 0.98-1.42, p=0.08) for hospitalisation; 1.21 (95% CI 0.97-1.51, p=0.09) for intensive care unit (ICU) admission; 1.06 (95% CI 0.82-1.36, p=0.65) for ventilator use; and 0.94 (95% CI 0.76-1.17, p=0.58) for mortality for people with asthma. Subgroup analyses by continent revealed a significant difference in risk of acquiring COVID-19, ICU admission, ventilator use and death between the continents. INTERPRETATION: The risk of being infected with severe acute respiratory syndrome coronavirus 2 was reduced compared to the non-asthma group. No statistically significant differences in hospitalisation, ICU admission and ventilator use were found between groups. Subgroup analyses showed significant differences in outcomes from COVID-19 between America, Europe and Asia. Additional studies are required to confirm this risk profile, particularly in Africa and South America, where few studies originate.
引用
- Sunjaya AP, Allida SM, Di Tanna GL, et al. Asthma and COVID-19 risk: a systematic review and meta-analysis. Eur Respir J. 2022. PMID: 34385278. doi:10.1183/13993003.01209-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。